CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

CTI BioPharma Corp.Dec 1 2014

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentations of data highlighting pacritinib, an oral multikinase inhibitor with dual activity against JAK2 and FLT3, and tosedostat, an oral selective inhibitor of aminopeptidases, at the 56^th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9 in San Francisco, CA.

The presentations will include data on the activity of pacritinib in stroma adherent acute myeloid leukemia (AML) cells, a profile of kinase inhibition across several cell signaling pathways with pacritinib treatment and analysis of a Phase 2 trial of treatment with tosedostat in combination with cytarabine or decitabine in patients with AML or myelodysplastic syndrome (MDS). A summary of the presentations is below, and full abstracts can be accessed on the ASH website at www.hematology.org.

Oral Presentation

Pacritinib Suppresses Leukemic Outgrowth from FLT3-ITD Positive Stroma-Adherent Primary AML Cells
First Author: Ceri Marrin, MBBCh, Department of Haematology, Institute of Cancer & Genetics, Cardiff University, Cardiff, United Kingdom
Date/Time: Monday, December 8 at 8:15 a.m. PT
Location: South Building, Esplanade 301 (Moscone Center)
Oral Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Molecular Targets and Drug Sensitivity in Myeloid Diseases
Abstract #270

Poster Presentations

Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis
First Author: Jack Singer, M.D., CTI BioPharma, Seattle, WA
Date/Time: Saturday, December 6 at 5:30-7:30 p.m. PT
Location: West Building, Level 1 (Moscone Center)
Poster Session: 635. Myeloproliferative Syndromes: Basic Science: Poster I
Abstract #1874

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
First Author: Raya Mawad, M.D., Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
Date/Time: Monday, December 8 at 6:00-8:00 p.m. PT
Location: North Building, Hall E (Moscone Center)
Poster Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
Abstract #3690